Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Update

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the target of a large decrease in short interest in the month of October. As of October 15th, there was short interest totalling 48,700 shares, a decrease of 50.7% from the September 30th total of 98,700 shares. Currently, 1.4% of the company’s shares are short sold. Based on an average daily volume of 2,400,000 shares, the days-to-cover ratio is presently 0.0 days.

Windtree Therapeutics Stock Performance

Windtree Therapeutics stock opened at $0.86 on Friday. The firm has a 50 day moving average price of $4.02 and a two-hundred day moving average price of $4.75. Windtree Therapeutics has a 52-week low of $0.66 and a 52-week high of $22.36. The firm has a market cap of $511,310.40, a price-to-earnings ratio of -0.02 and a beta of 0.55.

Windtree Therapeutics (NASDAQ:WINT) last issued its earnings results on Monday, August 19th. The company reported ($20.91) EPS for the quarter, missing the consensus estimate of ($8.11) by ($12.80). As a group, equities research analysts predict that Windtree Therapeutics will post -2.38 EPS for the current fiscal year.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.